Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31532645 | 1.00 | RYR2 (0.70) | RYR2KCNH2 | |
| SCHEMBL3430378 | 0.93 | RYR2 (0.70) | RYR2KCNH2 | |
| SCHEMBL3426026 | 0.92 | RYR2 (0.58) | RYR2KCNH2 | |
| SCHEMBL3426977 | 0.87 | RYR2 (0.53) | RYR2 | |
| SCHEMBL3427198 | 0.87 | RYR2 (0.53) | RYR2KCNH2 | |
| SCHEMBL6885187 | 0.85 | RYR2 (0.67) | RYR2KCNH2 | |
| SCHEMBL13694432 | 0.85 | RYR2 (0.50) | RYR2 | |
| SCHEMBL3427846 | 0.84 | RYR2 (0.50) | RYR2 | |
| SCHEMBL7991640 | 0.84 | RYR2 (0.49) | RYR2 | |
| SCHEMBL3428542 | 0.83 | RYR2 (0.77) | RYR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302847-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | RYCARMA THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| US-20250170144-A1 | CRYSTALLINE FORMS OF A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | RYCARMA THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-12161650-B2 | Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof | ARMGO PHARMA, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| EP-4433062-A1 | THERAPEUTIC COMPOUNDS | Armgo Pharma, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| US-12076326-B2 | Crystalline forms of a ryanodine receptor modulator and uses thereof | ARMGO PHARMA, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-12076327-B2 | Crystalline forms of a ryanodine receptor modulator and uses thereof | ARMGO PHARMA, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-12059426-B2 | Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof | ARMGO PHARMA, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| EP-4340861-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | Armgo Pharma, Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20230372358-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | RYCARMA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230372358-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | RYCARMA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20130281512-A1 | AGENTS FOR TREATING DISORDERS INVOLVING MODULATION OF RYANODINE RECEPTORS | ARMGO PHARMA, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| EP-2653466-A1 | Agents for treating disorders involving modulation of ryanodine receptors | Les Laboratoires Servier (FR) | 2013-10-23 | — | — | EP | disclosed |
| EP-2653466-A1 | Agents for treating disorders involving modulation of ryanodine receptors | Les Laboratoires Servier (FR) | 2013-10-23 | — | — | EP | disclosed |
| EP-2250159-B1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | ARMGO PHARMA INC (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2250159-B1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | ARMGO PHARMA INC (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2250159-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | Armgo Pharma, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009111463-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | ARMGO PHARMA, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227788-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | RYCARMA THERAPEUTICS, INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090227788-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | RYCARMA THERAPEUTICS, INC. | 2009-09-10 | — | — | US | disclosed |
| US-20090227788-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | RYCARMA THERAPEUTICS, INC. | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302847-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | RYR1, RYR2, MUSK | RYR2 2/4885KCNH2 1132/4885 |
| US-12076326-B2 | Crystalline forms of a ryanodine receptor modulator and uses thereof | RYR1, RYR2, ATP2A1 | RYR2 2/4885KCNH2 1249/4885 |
| US-12076327-B2 | Crystalline forms of a ryanodine receptor modulator and uses thereof | RYR1, RYR2, ATP2A1 | RYR2 2/4885KCNH2 1249/4885 |
| US-20090227788-A1 | PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES | TPMT, SULT2A1, KCNJ2 | RYR2 547/4885KCNH2 103/4885 |
| US-12059426-B2 | Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof | RYR1, RYR2, MUSK | RYR2 2/4885KCNH2 1132/4885 |
| US-12161650-B2 | Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof | RYR1, RYR2, MUSK | RYR2 2/4885KCNH2 1132/4885 |
| US-20130281512-A1 | AGENTS FOR TREATING DISORDERS INVOLVING MODULATION OF RYANODINE RECEPTORS | RYR1, RYR2, ATP2A1 | RYR2 2/4885KCNH2 233/4885 |
| US-20250170144-A1 | CRYSTALLINE FORMS OF A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | RYR1, RYR2, ATP2A1 | RYR2 2/4885KCNH2 1249/4885 |
| US-20230372358-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF | RYR1, RYR2, MUSK | RYR2 2/4885KCNH2 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.